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TECHNICAL NOTE
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In normal subjects the major route of digoxin elimination is
renal, with digoxin clearance approximating glomerular filtra-
tion rate; the maintenance of good renal perfusion and urine
flow is vital for the resolution of digoxin toxicity. In subjects
with renal failure digoxin half-life is much prolonged [1] and
digoxin toxicity can be protracted. We report the clinical course
and characteristics of XAD-4 hemoperfusion in three patients
with renal failure and refractory manifestations of digoxin
toxicity.
Methods and Results. Conduct of hernoperfitsions. Car-
tridges of XAD-4 resin were used for each hemoperfusion (HP).
Inflow (A) and outflow (V) blood samples were taken regularly
for digoxin measurements. Plasma digoxin was quantified by
radioimmunoassay. RBC-surface digoxin and total RBC digox-
in were measured by radioimmunoassay with Immunobeads
and J125 digoxin tracer (Quantimmune Digoxin RIA Kit, Bio-
Rad Laboratories, Richmond, California) with preparations of
washed packed unlysed and lysed RBCs. The extraction frac-
tion of digoxin by the resin was calculated (A—V/A) and the
digoxin clearance from plasma and RBCs cells derived. Digoxin
was eluted from the used columns by methanol extraction and
quantitated [2]. Mean digoxin clearance was calculated from the
amount of digoxin recovered (digoxin recovered/mean inflow
digoxin concentration).
Case reports: Patient / (Table I). The patient had chronic
renal failure and had been taking 0.125 mg digoxin per day. She
developed nausea, vomiting, abdominal pain, diarrhea, blurred
vision, distorted color perception, variable first and second
degree and complete heart block (ventricular rate of 28/mm),
and multiple ventricular premature beats (VPB5). There was no
improvement over 48 hr. so XAD-4 HP was undertaken. During
HP rhythm changed to sinus mechanism with first degree heart
block at 60 to 70 beats/mm, and VPBs subsided. Noncardiac
symptoms resolved and did not recur. Several hours after HP
second degree heart block with VPBs recurred, so HP was
repeated. During treatment the arrhythmias resolved perma-
nently. The P-R interval and heart rate normalized.
The extraction of digoxin from the plasma remained excellent
throughout both procedures. Calculated mean plasma digoxin
clearances were 156 mI/mm for the first treatment and 167 ml/
79
mm for the second treatment. The plasma TV2 of digoxin
shortened dramatically during each HP. The amount of digoxin
recovered from the cartridge exceeded the calculated quantity
of digoxin extracted from the plasma, suggesting that digoxin
was also being cleared from formed blood elements, perhaps
RBCs [2]. The whole blood digoxin clearance, calculated from
recovered digoxin, was 218 ml/min for the first HP and 293 ml/
mm for the second HP. Plasma digoxin rebounded to a level
intermediate between pre- and postperfusion values after each
hemoperfusion. The 342 removed during II hr of HP
represents 65.8% of an ideal intravenous loading dose (10 g/
kg), or four pills of 0.125 mg at 67% absorption [1], or 4 days'
worth of her previous maintenance dose.
Patient 2 (Table 2). This diabetic maintenance hemodialysis
patient, became digitoxic, with intractable nausea and vomiting
and profound hypotension during dialysis. Digoxin was discon-
tinued, but symptoms worsened over the next 48 hr. HP was
undertaken using a forearm fistula for blood access. Nausea and
vomiting cleared dramatically. Treatment was discontinued
when the arterial needle became dislodged. Hemodialysis was
then conducted without complications. The digoxin level re-
bounded to 5.2 ng/ml but his symptoms remained improved;
hemodialysis was again uneventful and HP was not repeated.
Extraction of digoxin from the plasma was excellent and well
maintained. Plasma T½ of digoxin was reduced dramatically.
RBC-surface digoxin concentration was approximately equal to
that of plasma, and digoxin was extracted with efficiency
approaching that of plasma digoxin extraction. Calculated di-
goxin removal in a 5.25-hr treatment was 246 g, or 3 days'
worth of his previous maintenance dose at 67% absorption, or
34% of a therapeutic loading dose.
Patient 3 (Table 3). A patient with atrial fibrillation and
congestive heart failure underwent surgery for small bowel
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strangulation and developed acute renal failure, He received his
usual maintenance dose of (1.125 mg of digoxin for 4 days and
developed episodic nodal rhythm, frequent VPBs, ventricular
bigeminy, and runs of ventricular tachycardia not suppressed
by lidocaine. HP was performed with hifemoral venous cathe-
terization. The episodes of nodal rhythm disappeared and the
VPBs and runs of ventricular tachycardia became much less
frequent and were more easily suppressed. Due to misinterpre-
tation of the significance of high pressures in the inflow line, a
fresh cartridge was substituted after 3.25 hr.
Extraction of plasma digoxin was excellent throughout the
entire procedure. The plasma TV2 of digoxin was shortened
during HP. RBC digoxin (not shown) and RBC-surface digoxin
were approximately equal, suggesting that most RBC digoxin
was surface-associated, Most RBC digoxin was extracted dur-
ing each pass through the cartridge, although the extraction
fraction was somewhat less than simultaneous plasma digoxin
extraction. The calculated total digoxin clearance at a blood
flow rate of 350 mI/mm was 280 mI/mm, more than three times
renal digoxin clearance for a comparable normal 98-year-old
man. Calculated digoxin recovery was 243 tg, or 2 days' worth
of his previous parenteral maintenance dose, or 36.3% of a
therapeutic loading dose.
Discussion. In these three patients with renal thilure XAD-4
HP removed digoxin at a rate exceeding normal renal digoxin
clearance, greatly reduced plasma T¼ digoxin, cleared digoxin
from RBCs, and ameliorated symptoms and signs of
digitoxicity.
Digoxin in the blood compartment is distributed in plasma,
where 25% is protein-bound in normal subjects (perhaps less in
uremics), and in RBCs, where it is largely bound to surface
Naf K+ ATPase [1, 3]. In our studies the extraction ofdigoxin
from the plasma by the resin was extremely efficient, and the
negligible or low outflow digoxin concentrations during most of
the procedures indicate that protein-bound as well as free
digoxin was probably removed. Digoxin was also extracted
from RBC membranes with an efficiency only slightly less than
that of plasma digoxin extraction. There was only a modest
decline in extraction fraction during each procedure. Plasma
and whole blood digoxin clearances greatly exceeded renal
digoxin clearance in comparable patients with normal renal
function. Plasma and RBC digoxin were removed at a rate
greater than the ability of tissue stores to equilibrate with the
blood compartnient. Thus, quantitative digoxin extraction pro-
gressively decreased throughout each procedure despite main-
tenance of high clearances, and plasma digoxin rebounded to
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Table 1. XAD-4 hemoperfusion in patient 1: 40 years old, female, 52 kg, Ut 2591, Kt 4.7 mEq/liter, Cc. 3 mI/mm
Plasma digoxin
Time — Dig R
hours A V EF Cl T½ p-g
Pre HP #1
—44.5 6.9
—6.5 4.8
HP#l 68
Start
CIR (Dig R)
0 4.3
0.5 190 141 3.6 <0.5" 0.95 131
1.5 212 157 2.9 0.5 0.83 130
2.5 212 157 2.4 0.5 0.79 124
3.5 250 190 2.3 <0.5 0.89 169
4.5 250 190 2.3 0.6 0.74 141
5.5 250 190 2.2 0.5 0.77 146
End
7.5 3.0
9.5 3.2
13.5 3.3
17.5 3.3
25.5 3.0
HP #2
Start
0 3.0 <0.5
1 250 195 2.0 <0.5 0.88 171
2 250 195 1.8 <0.5 0.86 168
3 250 195 1.6 <0.5 0.83 161
4 250 195 1.4 <0.5 0.82 160
5 250 195 1.3 <0.5 0.81 157
6 250 195 1.3 <0.5 0.8! 157
72
5.8 163 218
5.6 179 293
End
14 2.6
38 2.6
Abbreviations: flt, hematocrit; Kt, serum potassium concentration; C( . creatinine clearance: HP, XAD-4 hemoperfusion; Q. blood flow rate in
milliliters per minute; Qp, calculated plasma flow raie in milliliters per minute; A, inflow digoxin concentration in nanograms per milliliter; V.
outflow digoxin concentration in nanograms per milliliter; Plasma T1/2 digoxin, disappearance half-time of digoxin from plasma; [F, digoxin
extraction fraction; Cl, digoxin clearance in milliliters per minute; Dig R, digoxin recovered from used cartridge: Cl (Dig R), mean whole blood di-
goxin clearance calculated from recovered digoxin in milliliters per minute (sec text).
For digoxin levels <0.5 ng/ml extraction and clearance calculations are based on an assumed lcvcl of 0.25 ng/ml.
For abbreviations, see Table I.
levels intermediate between pre- and postprocedure levels,
several hours after HP was discontinued.
The usefulness of this treatment for digoxin toxicity is
disputed, even in patients with renal failure. It has been stated
that for drugs with large volumes of distribution, such as
digoxin, clearance of the plasma compartment, however effi-
cient, could not remove enough drug to ameliorate toxicity [4].
We counter with the following arguments: First, the toxic!
therapeutic ratio of digoxin is very low, and the removal of the
modest amounts of drug would, in most cases, be sufficient to
reverse toxicity. Second, the volume of distribution of digoxin
is reduced in subjects with renal failure, so they require less
digoxin to achieve therapeutic and toxic levels and less digoxin
removal to reverse toxicity. In addition a greater proportion of
the drug is present in the blood compartment and readily
available for extraction [5, 6]. Third, the calculated or quanti-
fled amount of digoxin removed from these patients was
considerable, representing a significant proportion of an ideal
loading dose of digoxin for patients with renal failure which was
10 pg/kg [61, and 2 to 4 days' worth of their previous mainte-
nance doses. Fourth, digoxin clearance by HP greatly exceeded
normal renal digoxin clearances. The maintenance of optimal
renal digoxin clearance is the cornerstone of management of
any digitoxic patient, and the reason for digoxin toxicity in most
patients with renal insufficiency is their lack of normal renal
digoxin excretion. The resolution of digoxin toxicity should be
hastened by supplying to such subjects, albeit temporarily,
digoxin clearances greater than normal renal digoxin clearance.
Fifth, improvement in digitoxic symptoms and signs was ob-
served in all patients studied, with each treatment.
Our experience indicates that treatment is most efficient at
high blood flow rates, because, while extraction fraction might
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Table 2. XAD-4 hemoperfusion in patient 2: 63 years old, 72 kg, Ht 26%, K 5.5 mEq/liter, C. 2 ml/min
Total digoxin
Plasma digoxin RBC-surface digoxin clearance
______________________________ ________________ - - (plasma + RBC)
Qu Q, A V EF Cl T½ A V EF Cl mi/mm
Time
hours
HP
Start
0
0.05
1.25
2.25
3.25
4.25
5.25
175 130 6.2
200 152 5.4
200 152 4.4
250 (85 4.6
250 185 4.4
250 185 3.8
250 185 3.6
0.3 0.94
0.6 0.86
1.0 0.78
1.2 0.73
1.2 0.68
1.0 0.72
139
127
144
135
124
133
5.0 0.9 0.82 31
4.0 1.2 0.70 46
4.0 1.1 0.73 47
End
6.75 4.2
8.75 5.0
10.75 5.2
19.25 5.0 76
41.25 4.9
53.25 3.5
77.25 3.3
For abbreviations, see Table 1.
Table 3. XAD-4 hemoperfusion patient 3: 98 years old, 67 kg, Ht 28%, K 4.7 mEq/liter, C 4.6 m1/min
Plasma digoxin RBC-surface digoxin
Time
hours QB Qp A V EF Cl TV2 A V EF Cl
Pre HP
—12.5 4.0
HP
Start
170
181
170
Total digoxin
clearance
(plasma + RBC)
mi/mm
54.5
End
14.25
0 100 72 3.4 4.3
0.25 350 252 3.! <0.5 0.92 229 4.0 0.8 0.80 81 310
1.25 350 252 2.5 <0.5 0.90 224 3.0 1.1 0.63 64 288
2.25 350 252 2.2 <0.5 0.89 222 2.6 (.3 0.50 59 281
3.25 350 252 2.1 <0.5 0.89 219 4.8 2.4 2.0 0.20 20 239
4.25 350 249 1.8 <0.5 0.86 2(4 2.5 0.5 0.80 81 295
5.25 350 249 1.6 <0.5 0.84 210 2.5 0.8 0.68 69 279
6.25 350 249 1.6 <0.5 0.84 210 2.1 0.7 0.67 68 278
6.75 350 249 1.6 <0.5 0.84 210 2.2 0.9 0.59 60 270
2.5
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decline as flow increases, this is probably outweighed by the
increased clearances achicved. Owing to slow equilibration of
tissue storcs with the blood compartment, quantitative digoxin
extraction would also be maximized by several short treatments
(if needed) separated by a few hours to allow equilibration and
rebound of blood levels, rather than a single protracted
treatment.
We feel that XAD-4 hemoperfusion properly performed can
abbreviate the course of digoxin toxicity in patients with renal
failure and deserves wider appliealion and investigation.
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